Soluble Isoforms of Vascular Endothelial Growth Factor Are Predictors of Response to Sunitinib in Metastatic Renal Cell Carcinomas

Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers

(2009) Loukas F Kontovinis et al.   BMC CANCER

Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

(2009) Bernard Escudier et al.   JOURNAL OF CLINICAL ONCOLOGY

Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma

(2008) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Sorafenib for Older Patients With Renal Cell Carcinoma: Subset Analysis From a Randomized Trial

(2008) T. Eisen et al.   JNCI-Journal of the National Cancer Institute

VEGF and VEGFR-1 are coexpressed by epithelial and stromal cells of renal cell carcinoma

(2007) Jacqueline Rivet et al.   CANCER

Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma

(2007) Toni K. Choueiri et al.   JOURNAL OF CLINICAL ONCOLOGY